Skip to content
Altius – Lifestyle
Author:
Cyclarity Therapeutics
Cyclarity Therapeutics Receives FDA Investigational New Drug Clearance for UDP-003 to expand Atherosclerosis Clinical Development Program into the United States
November 12, 2026